Referring to this work and to previously published results [9] that showed no significant effect of OA, HIMOXOL, and Br-HIMOLID on non-cancer MCF-12A breast cells, we might conclude that both oleanolic acid derivatives might constitute an important element in planning further HER2-positive-targeted breast cancer therapy strategy. This evidence concerns the gene ERBB2 and breast carcinoma.